XML 36 R23.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Stock Incentive Plan | 12 Months Ended
--- | ---
Dec. 31, 2021
Stockholders' Equity Note [Abstract] |
Stock Incentive Plan |
15. | STOCK INCENTIVE PLAN
General—The Company has a stock incentive plan (the “Stock Incentive Plan”) and an employee stock purchase plan (the “ESPP”) that are administered by the Compensation and Talent Development Committee of the Board of Directors. Under the Stock Incentive Plan, the Company can issue shares to employees and directors in the form of restricted stock awards (“RSAs”), restricted stock units (“RSUs”), and performance share units (“PSUs”). Compensation expense recognized related to the Company’s Stock Incentive Plan was $11,687, $11,572 and $3,761 for 2021, 2020 and 2019, respectively. Under our 2018 Stock Incentive Plan, we are authorized to issue 3,400 shares, and assuming PSU vestings occur at maximum payout, 882 authorized shares remained available under our Stock Incentive Plan for future grants at December 31, 2021. Under the ESPP, employees may make quarterly purchases of shares at a discount through regular payroll deductions for up to 15% of their compensation, subject to a $25 maximum purchase per year. The shares are purchased at 85% of the closing price per share on the last trading day of the calendar quarter. Included within total stock-based compensation expense is $84, $71 and $27 of expense related to the ESPP, for 2021, 2020 and 2019, respectively. ESPP expense represents the difference between the fair value on the date of purchase and the price paid. At December 31, 2021, 725 authorized shares remained available for issuance under the ESPP. Total equity-based compensation expense recognized related to the Company’s Stock Incentive Plan and the ESPP was $11,771, $11,643 and $3,788 for 2021, 2020 and 2019, respectively, primarily recognized within general and administrative expenses. At December 31, 2021, there was approximately $6,300 of unrecognized compensation cost related to equity-based grants, which is expected to be recognized over a weighted-average period of 1.2 years. The Company recognizes forfeitures as they occur, rather than estimating expected forfeitures. RSAs—The Company’s RSA awards may not be sold or otherwise transferred until certain restrictions have lapsed, which is generally over a three-year graded vesting period for employees and over one year for Directors. The total initial fair value for these awards is determined based upon the market price of our stock at the grant date and is expensed on a straight-line basis over the vesting period. During 2021, we recognized $646 of compensation expense. The following table presents RSA activity during 2021:
RSAs |  | Number of Shares |  | Weighted Average Fair Value Per Share
Balance at December 31, 2020 |  | 55 |  |  | $ | 9.26 |
Granted |  | 29 |  |  | $ | 23.19 |
Vested |  | (55) |  |  | $ | 9.26 |
Forfeited |  | — |  |  | $ | — |
Balance at December 31, 2021 |  | 29 |  |  | $ | 23.19 |
During 2020, 51 RSAs were granted with a weighted-average grant-date fair value per share of $8.73. During 2019, 52 RSAs were granted with a weighted-average grant-date fair value per share of $12.06. The total fair value of RSAs that vested during 2021, 2020 and 2019 was $506, $799 and $1,261, respectively. RSUs—The Company’s RSU awards may not be sold or otherwise transferred until certain restrictions have lapsed, which is generally over a three-year graded vesting period. The total initial fair value for these awards is determined based upon the market price of our stock at the grant date and is expensed on a straight-line basis over the vesting period. During 2021, we recognized $2,128 of compensation expense. The following table presents RSU activity during 2021:
RSUs | Number of Shares |  | Weighted Average Fair Value Per Share
Balance at December 31, 2020 | 287 |  |  | $ | 13.77 |
Granted | 151 |  |  | $ | 21.29 |
Vested | (182) |  |  | $ | 15.05 |
Forfeited | (6) |  |  | $ | 14.06 |
Balance at December 31, 2021 | 250 |  |  | $ | 17.37 |
During 2020, 169 RSUs were granted with a weighted-average grant-date fair value per share of $13.52. During 2019, 261 RSUs were granted with a weighted-average grant-date fair value per share of $12.14. The total fair value of RSUs that vested during 2021, 2020 and 2019 were $2,742, $2,918, and $1,709, respectively. PSUs—The Company’s performance-based share awards are subject to the achievement of specified financial based performance targets and are generally based upon EPS and vest over three years. The total initial fair value for these awards is determined based upon the market price of our stock at the grant date applied to the total number of shares. This fair value is expensed and adjusted over the vesting period based on the level of payout expected to be achieved. As a result of financial performance conditions met during 2021, we recognized $8,913 of compensation expense. During 2021, 2020 and 2019, PSU shares totaling 397, 176 and 310, respectively, were granted with a weighted-average grant-date fair value per share of $21.88, $14.06 and $11.81, respectively. During 2021, upon vesting and achievement of certain performance goals, we distributed 658 shares of common stock related to PSU awards with a weighted-average grant- date fair value per share of $11.91. The total fair value of PSUs that vested during 2021, 2020 and 2019 was $7,842, $1,620 and $948, respectively. Shares Withheld for Taxes—The Company withheld 311, 123 and 74 shares for taxes on RSU and PSU stock-based compensation vestings for $7,311, $1,845 and $964 during 2021, 2020 and 2019, respectively. The Company withheld 1, 11 and 17 shares for taxes on RSA stock-based compensation vestings for $27, $140 and $255 during 2021, 2020 and 2019, respectively. Warrants—On April 3, 2017, the Company issued warrants (the “Warrants”) to the lenders under the Oaktree Facility (the “Holders”) pursuant to which such holders have the right to purchase, for a period of 5 years from the date of issuance, up to an aggregate of 1,000 shares of the Company’s common stock (the “Warrant Shares”) at an initial exercise price of $10.25 per share. The Company valued these Warrants using the Black-Scholes model, which is a type 3 fair value measurement. The key assumptions used in the Black-Scholes Model and fair value output are summarized in the table below:
| April 3, 2017
Stock price at grant date | $ | 8.88 |
Exercise option price | $ | 10.25 |
Expected term of warrants (in years) | 5
Expected volatility rate | 48.29 | %
Risk-free rate | 1.88 | %
Expected dividend yield | — | %
Total fair value | $ | 3,500 |
During 2021, certain holders exercised 530 warrants, elected the cashless exercise option, and the Company issued 315 common shares with a market value of $8,082. During 2020, certain holders exercised 470 warrants, elected the cashless exercise option, and the Company issued 110 common shares with a market value of $1,477. There were no exercises during 2019. At December 31, 2021, no warrants remained outstanding.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration